Advertisement
Advertisement

SDEV

S

Stablecoin Development Corporation

1.41
USD
Sponsored
-0.07
-4.73%
May 22, 16:00 UTC -4
Closed
exchange

After-Market

1.40

-0.01
-0.50%

Stablecoin Development Corporation Profile

About

NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative product candidates targeting the treatment or prevention of a wide range of infections in hospital and non-hospital environments. NovaBay has discovered and is developing a class of antimicrobial compounds, which it has named Aganocide compounds, which are based upon small molecules that are generated by white blood cells that defend the body against invading pathogens. NovaBay believes that Aganocide compounds could form a platform on which to create a variety of products to address differing needs in the treatment and prevention of bacterial and viral infections, including Methicillin-Resistant Staphylococcus aureus.

Info & Links

CEO

Michael Kazley

Headquarters

2000 POWELL STREET, SUITE 1150
EMERYVILLE, CA 94608, UNITED STATES

Industry

Other

Sector

Other

Website

https://novabay.com

Auditor

CBIZ CPAs P.C.

Share holders

97

Employees

4

Stablecoin Development Corporation Statistics

Valuation Measures

Market Capitalization2

38.04M

Enterprise Value

19.64M

Enterprise Value/EBITDA(ttm)

1.10

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

--

Price to Book(mrq)

--

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

2.02%

Operating Margin(ttm)

--

Profit Margin(ttm)

-62.04%

Return on Equity(ttm)

-445.74%

Return on Invested Capital(ttm)

-65.33%

Return on Assets(ttm)

-453.46%

Income Statement

Revenue(ttm)

25.66M

Revenue Per Share(ttm)

0.95

Gross Profit(ttm)

25.18M

EBITDA(ttm)3

17.91M

Net Income Available to Common(ttm)

522.59M

Diluted EPS(ttm)

--

Share Statistics

Beta (5Y Monthly)

0.26

52-Week Change

--

S&P 500 52-Week Change

26.21%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

27.12M

Dividend Yield

0.00%

Float4

22.66M

% Held by Insiders

14.90%

% Held by Institutions

23.25%

Balance Sheet

Total Cash(mrq)

18.41M

Total Cash Per Share(mrq)

0.68

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

-0.29%

Current Ratio(mrq)

7.60%

Quick Ratio(mrq)

7.60%

Book Value Per Share(mrq)

-0.91

Cash Flow

Operating Cash Flow Per Share(ytd)

-1.45

Free Cash Flow(ytd)

-8.43M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement